MX349494B - Medios y metodos para tratar o diagnosticar canceres positivos a idh1 r132h mutante. - Google Patents
Medios y metodos para tratar o diagnosticar canceres positivos a idh1 r132h mutante.Info
- Publication number
- MX349494B MX349494B MX2014008306A MX2014008306A MX349494B MX 349494 B MX349494 B MX 349494B MX 2014008306 A MX2014008306 A MX 2014008306A MX 2014008306 A MX2014008306 A MX 2014008306A MX 349494 B MX349494 B MX 349494B
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- idh1
- amino acid
- cancer
- present
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 201000011510 cancer Diseases 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000027455 binding Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01042—Isocitrate dehydrogenase (NADP+) (1.1.1.42)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a terapéuticos y diagnóstico de tumor. Específicamente, se refiere a un péptido que comprende al menos 8 aminoácidos en longitud, los cuales están presentes como una secuencia de aminoácido contigua en Isocitrato dehidrogenasa Tipo 1 humana (IDH1), en donde dicho péptido tiene al menos un intercambio de aminoácido de R a H en una posición que corresponde a la posición 132, para usarse en la prevención y/o el tratamiento de cáncer. Además se contempla un medicamento que comprende dicho péptido. Además, la invención se refiere a un método para diagnosticar cáncer caracterizado por tener una mutación en el genoma de al menos algunas células cancerosas, que resulta en la expresión de una IDH1 mutante que tiene la mutación Rl132H, que comprende los pasos de poner en contacto una muestra sanguínea de un sujeto con sospecha de sufrir de dicho cáncer con un péptido que comprende al menos 10 aminoácidos en longitud, los cuales están presentes como una secuencia de aminoácido contigua en la IDH1, en donde dicho péptido tiene al menos un intercambio de aminoácido de R a H en una posición que corresponde a la posición 132 durante un tiempo y bajo condiciones que permiten la unión específica de un componente del sistema inmune al péptido, y determinar si ocurre, o no, la unión de dicho componente del sistema inmune al péptido, en donde el cáncer es diagnosticado si la ocurrencia de la unión ha sido determinada. También la invención proporciona un equipo y un dispositivo para llevar a cabo dicho método.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12150298 | 2012-01-05 | ||
| PCT/EP2013/050048 WO2013102641A1 (en) | 2012-01-05 | 2013-01-03 | Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014008306A MX2014008306A (es) | 2015-03-03 |
| MX349494B true MX349494B (es) | 2017-08-01 |
Family
ID=47559460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014008306A MX349494B (es) | 2012-01-05 | 2013-01-03 | Medios y metodos para tratar o diagnosticar canceres positivos a idh1 r132h mutante. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10161940B2 (es) |
| EP (1) | EP2800580B1 (es) |
| JP (1) | JP6316755B2 (es) |
| KR (1) | KR102055463B1 (es) |
| CN (1) | CN105142662B (es) |
| AU (1) | AU2013207191B2 (es) |
| BR (1) | BR112014016612A2 (es) |
| CA (1) | CA2859078A1 (es) |
| EA (1) | EA201491324A1 (es) |
| ES (1) | ES2642184T3 (es) |
| HK (1) | HK1203825A1 (es) |
| MX (1) | MX349494B (es) |
| SG (1) | SG11201403877PA (es) |
| WO (1) | WO2013102641A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019157279A1 (en) * | 2018-02-10 | 2019-08-15 | Berkeley Lights, Inc. | Mutant idh1 specific t cell receptor |
| CN112239787B (zh) * | 2019-07-19 | 2024-05-10 | 河南远止生物技术有限公司 | 一种检测人idh1基因突变的引物和探针、试剂盒和装置 |
| WO2021014398A1 (en) * | 2019-07-23 | 2021-01-28 | University Of Rijeka Faculty Of Medicine | Integrated human cytomegalovirus / glioblastoma vaccine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139371A0 (en) * | 1998-05-01 | 2001-11-25 | Texas A & M System | Feline dc80, feline cd86, feline dc28 and feline ctla-4 nucleic acid and polyptides |
| GB9810276D0 (en) * | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| ES2306528T3 (es) * | 1998-12-23 | 2008-11-01 | Id Biomedical Corporation | Antigenos de streptococcus. |
| EP2546365B1 (en) * | 2008-09-03 | 2016-11-09 | The Johns Hopkins University | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma |
| CN102985557B (zh) * | 2009-03-13 | 2018-06-15 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| JPWO2010110346A1 (ja) * | 2009-03-24 | 2012-10-04 | 独立行政法人理化学研究所 | 白血病幹細胞マーカー |
| EP2253716A1 (en) | 2009-05-15 | 2010-11-24 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Diagnostic methods for the prognosis of a brain tumor |
-
2013
- 2013-01-03 SG SG11201403877PA patent/SG11201403877PA/en unknown
- 2013-01-03 WO PCT/EP2013/050048 patent/WO2013102641A1/en active Application Filing
- 2013-01-03 KR KR1020147021779A patent/KR102055463B1/ko active IP Right Grant
- 2013-01-03 JP JP2014550699A patent/JP6316755B2/ja active Active
- 2013-01-03 EA EA201491324A patent/EA201491324A1/ru unknown
- 2013-01-03 BR BR112014016612A patent/BR112014016612A2/pt not_active Application Discontinuation
- 2013-01-03 CN CN201380004722.8A patent/CN105142662B/zh not_active Expired - Fee Related
- 2013-01-03 EP EP13700266.3A patent/EP2800580B1/en active Active
- 2013-01-03 MX MX2014008306A patent/MX349494B/es active IP Right Grant
- 2013-01-03 AU AU2013207191A patent/AU2013207191B2/en not_active Ceased
- 2013-01-03 US US14/370,224 patent/US10161940B2/en active Active
- 2013-01-03 ES ES13700266.3T patent/ES2642184T3/es active Active
- 2013-01-03 CA CA2859078A patent/CA2859078A1/en not_active Abandoned
-
2015
- 2015-05-07 HK HK15104348.4A patent/HK1203825A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014016612A2 (pt) | 2017-06-27 |
| CN105142662B (zh) | 2017-07-07 |
| SG11201403877PA (en) | 2014-09-26 |
| KR20140120324A (ko) | 2014-10-13 |
| EP2800580B1 (en) | 2017-07-12 |
| AU2013207191B2 (en) | 2017-10-26 |
| EA201491324A1 (ru) | 2015-03-31 |
| ES2642184T3 (es) | 2017-11-15 |
| US20150023991A1 (en) | 2015-01-22 |
| CA2859078A1 (en) | 2013-07-11 |
| JP6316755B2 (ja) | 2018-04-25 |
| HK1203825A1 (en) | 2015-11-06 |
| JP2015505246A (ja) | 2015-02-19 |
| AU2013207191A1 (en) | 2014-07-03 |
| CN105142662A (zh) | 2015-12-09 |
| WO2013102641A1 (en) | 2013-07-11 |
| US10161940B2 (en) | 2018-12-25 |
| EP2800580A1 (en) | 2014-11-12 |
| KR102055463B1 (ko) | 2019-12-12 |
| MX2014008306A (es) | 2015-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502200A1 (en) | Methods of diagnosing and treating cancer | |
| TN2013000358A1 (en) | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects | |
| WO2013022995A3 (en) | Biomarker compositions and methods | |
| WO2012174282A3 (en) | Biomarker compositions and methods | |
| MX2012002139A (es) | Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. | |
| MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| EA201391187A1 (ru) | Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток | |
| WO2014037588A3 (en) | Methods and compounds for preventing, treating and diagnosing an inflammatory condition | |
| MX2012014739A (es) | Novedoso anticuerpo para el diagnostico y/o pronostico de cancer. | |
| MX341191B (es) | Metodos y composiciones para diagnostico y prognosis de lesion renal y falla renal. | |
| MX357292B (es) | Método para detectar cáncer. | |
| MX2015000684A (es) | Metodo para detectar cancer. | |
| WO2012160563A3 (en) | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same | |
| WO2011047033A3 (en) | Biomarker for identification of melanoma tumor cells | |
| EP3486657A3 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| MY195045A (en) | Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer | |
| EP2569635A4 (en) | METHODS OF DIAGNOSING AND TREATING ENCEPHALITY OR EPILEPSY | |
| BR112013021056A2 (pt) | anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical | |
| MX343630B (es) | Medios y metodos para diagnosticar y tratar esclerosis multiple. | |
| MX349494B (es) | Medios y metodos para tratar o diagnosticar canceres positivos a idh1 r132h mutante. | |
| WO2011093606A3 (ko) | Pna 기반의 실시간 pcr 클램핑을 이용한 braf 돌연변이 검출 방법 및 키트 | |
| WO2014117680A3 (zh) | 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆 | |
| MY148542A (en) | A method for the assessment of cancer in a biological sample obtained from a subject | |
| WO2014153232A3 (en) | Methods and compositions for diagnosing preeclampsia | |
| TR201910508T4 (tr) | Prostat kanserinin tedavisi ve prostat kanseri hastalarına yönelik prognozun belirlenmesine yönelik bir yöntem. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |